Rosetta Genomics jumps on NY approval for kidney test


Rosetta Genomics (ROSG) soars 20% premarket as the company says the New York State Department of Health has granted conditional approval for ROSG's kidney cancer test.

"With this approval, [we] can offer the Rosetta Kidney Cancer Test in all 50 U.S. states," the company says. (PR)

From other sites
Comments (3)
  • User 13146982
    , contributor
    Comment (1) | Send Message
     
    I sold 4,000 shares at a loss after you reported that Aegis Capital downgraded Rosetta and put $3.50 at max for 1 year. I get killed
    every time I listen to an analyst. The problem we small investors have is getting good info on small stocks.
    9 Dec 2013, 11:15 AM Reply Like
  • Jonathan Bluhm
    , contributor
    Comments (403) | Send Message
     
    Aegis will probably upgrade them next month and put a $10 PT on them again.
    9 Dec 2013, 01:11 PM Reply Like
  • Jonathan Bluhm
    , contributor
    Comments (403) | Send Message
     
    Don't listen to the analysts. They're always late to the party. Get back in on ROSG now. October and November have been the best 2 months in their history, and they look like a breakout candidate for 2014.

     

    I just submitted an article highlighting their recent positive turn of events, check it out. It will hopefully be published today.
    9 Dec 2013, 01:10 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs